Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Maple Syrup Urine Disease Workup

  • Author: Olaf A Bodamer, MD, PhD, FAAP, FACMG; Chief Editor: Luis O Rohena, MD  more...
 
Updated: Nov 04, 2014
 

Laboratory Studies

Plasma amino acids should be evaluated to assess the elevation of branched-chain amino acids and to detect alloisoleucine. The detection of alloisoleucine is diagnostic for maple syrup urine disease (MSUD). Alloisoleucine may not appear until the sixth day of life, even when leucine levels are elevated. Transient elevations of branched-chain amino acids (without the presence of alloisoleucine) may develop in patients with ketotic hypoglycemia and in patients in the postabsorptive state. Plasma amino acid levels may also be artificially elevated in infants on total parental nutrition (TPN).

Urine organic acids should be analyzed using gas chromatography-mass spectrometry (GC-MS) to detect alpha-hydroxyisovalerate, lactate, pyruvate, and alpha-ketoglutarate. A random urine specimen is usually sufficient.

Newborn screening for MSUD is performed with tandem mass spectrometry using concentrations of leucine and isoleucine and the Fisher Ratio (branch-chain amino acids/phenylalanine and tyrosine) as diagnostic measures. Immediate treatment should follow the identification of affected newborn infants.

Enzyme activity can be measured in lymphocytes, cultured fibroblasts, or both, although this test is not required for diagnosis.

Molecular testing is available for the three genes that have been reported in patients with MSUD, namely for BCKDHA encoding BCKA decarboxylase (E1) alpha subunit gene (MSUD type 1A), BCKDHB encoding BCKA decarboxylase (E1) beta subunit gene (MSUD type 1B), and DBT encoding dihydrolipoyl transacylase (E2) subunit gene (MSUD type 2) (see also GeneTests).

Molecular confirmation should be sought in any patient with MSUD to confirm the diagnosis, to provide additional information about prognosis, to provide the basis for in-depth genetic counseling for the family, and to provide the basis for prenatal testing.

Prenatal diagnosis can be performed by measuring enzyme activity in cultured amniocytes or chorion villus cells, mutation analysis, or by measuring branch-chain amino acid concentrations in amniotic fluid. However, molecular analysis is the most reliable and therefore preferred method for prenatal diagnosis. An important prerequisite is the identification of two pathogenic mutations in the index patient.

 
 
Contributor Information and Disclosures
Author

Olaf A Bodamer, MD, PhD, FAAP, FACMG Park Gerald Chair in Genetics and Genomics, Associate Chief, Division of Genetics and Genomics, Department of Medicine, Boston Children's Hospital, Harvard Medical School

Olaf A Bodamer, MD, PhD, FAAP, FACMG is a member of the following medical societies: American Medical Association, American Society of Human Genetics

Disclosure: Nothing to disclose.

Coauthor(s)

Brendan Lee, MD, PhD Professor, Robert and Janice McNair Endowed Chair in Molecular and Human Genetics, Department of Molecular and Human Genetics, Baylor College of Medicine

Brendan Lee, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, Society for Pediatric Research

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Biomarin; Retrophin;.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lois J Starr, MD, FAAP Assistant Professor of Pediatrics, Clinical Geneticist, Munroe Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center

Lois J Starr, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics

Disclosure: Nothing to disclose.

Chief Editor

Luis O Rohena, MD Chief, Medical Genetics, San Antonio Military Medical Center; Assistant Professor of Pediatrics, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Assistant Professor of Pediatrics, University of Texas Health Science Center at San Antonio

Luis O Rohena, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Additional Contributors

Christian J Renner, MD Consulting Staff, Department of Pediatrics, University Hospital for Children and Adolescents, Erlangen, Germany

Disclosure: Nothing to disclose.

References
  1. Menkes JH, Hurst PL, Craig JM. A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics. 1954 Nov. 14(5):462-7. [Medline].

  2. Chuang DT. Maple syrup urine disease: it has come a long way. J Pediatr. 1998 Mar. 132(3 Pt 2):S17-23. [Medline].

  3. Dancis J, Levits M, Westall RG. Maple syrup urine disease: branched-chain keto-aciduria. Pediatrics. 1960 Jan. 25:72-9. [Medline].

  4. Snyderman SE, Norton PM, Roitman E, Holt LE Jr. Maple syrup urine disease, with particular reference to dietotherapy. Pediatrics. 1964 Oct. 34:454-72. [Medline].

  5. Scriver CR, Mackenzie S, Clow CL, Delvin E. Thiamine-responsive maple-syrup-urine disease. Lancet. 1971 Feb 13. 1(7694):310-2. [Medline].

  6. Chuang DT, Shih VE. Maple syrup urine disease. Scriver CR, Beaudet AL, Valle DL, Sly WS, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill Co; 2000.

  7. Harris RA, Joshi M, Jeoung NH, Obayashi M. Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. J Nutr. 2005 Jun. 135(6 Suppl):1527S-30S. [Medline].

  8. Park HD, Lee DH, Hong YH, Kang DH, Lee YK, Song J, et al. Three Korean patients with maple syrup urine disease: four novel mutations in the BCKDHA gene. Ann Clin Lab Sci. 2011 Spring. 41(2):167-73. [Medline].

  9. Henneke M, Flaschker N, Helbling C, et al. Identification of twelve novel mutations in patients with classic and variant forms of maple syrup urine disease. Hum Mutat. 2003 Nov. 22(5):417. [Medline].

  10. Fernstrom JD. Branched-chain amino acids and brain function. J Nutr. 2005 Jun. 135(6 Suppl):1539S-46S. [Medline].

  11. Yudkoff M, Daikhin Y, Nissim I, et al. Brain amino acid requirements and toxicity: the example of leucine. J Nutr. 2005 Jun. 135(6 Suppl):1531S-8S. [Medline].

  12. Quental S, Macedo-Ribeiro S, Matos R, Vilarinho L, Martins E, Teles EL, et al. Molecular and structural analyses of maple syrup urine disease and identification of a founder mutation in a Portuguese Gypsy community. Mol Genet Metab. 2008 Jun. 94(2):148-56. [Medline].

  13. Hoffmann GF, von Kries R, Klose D, et al. Frequencies of inherited organic acidurias and disorders of mitochondrial fatty acid transport and oxidation in Germany. Eur J Pediatr. 2004 Feb. 163(2):76-80. [Medline].

  14. Morton DH, Strauss KA, Robinson DL, et al. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics. 2002 Jun. 109(6):999-1008. [Medline].

  15. Hallam P, Lilburn M, Lee PJ. A new protein substitute for adolescents and adults with maple syrup urine disease (MSUD). J Inherit Metab Dis. 2005. 28(5):665-72. [Medline].

  16. Wendel U, Saudubray JM, Bodner A, Schadewaldt P. Liver transplantation in maple syrup urine disease. Eur J Pediatr. 1999 Dec. 158 Suppl 2:S60-4. [Medline].

  17. Mazariegos GV, Morton DH, Sindhi R, Soltys K, Nayyar N, Bond G, et al. Liver Transplantation for Classical Maple Syrup Urine Disease: Long-Term Follow-Up in 37 Patients and Comparative United Network for Organ Sharing Experience. J Pediatr. 2012. 160:116-121. [Medline].

  18. Heldt K, Schwahn B, Marquardt I, et al. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification. Mol Genet Metab. 2005 Apr. 84(4):313-6. [Medline].

  19. Hoffmann B, Helbling C, Schadewaldt P, Wendel U. Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD. Pediatr Res. 2006 Jan. 59(1):17-20. [Medline].

  20. Mitsubuchi H, Owada M, Endo F. Markers associated with inborn errors of metabolism of branched-chain amino acids and their relevance to upper levels of intake in healthy people: an implication from clinical and molecular investigations on maple syrup urine disease. J Nutr. 2005 Jun. 135(6 Suppl):1565S-70S. [Medline].

  21. Righini A, Ramenghi LA, Parini R, et al. Water apparent diffusion coefficient and T2 changes in the acute stage of maple syrup urine disease: evidence of intramyelinic and vasogenic-interstitial edema. J Neuroimaging. 2003 Apr. 13(2):162-5. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.